The study offers an in‑depth look at how RECIST 1.1 progression events are defined and where variability between independent readers can emerge. By shedding light on the mechanisms that influence PD assessments, this work provides valuable insights for strengthening the reliability and consistency of imaging endpoints in oncology trials.

These insights bring tangible value to both sponsors and CROs, helping teams better anticipate imaging‑related risks, design stronger study frameworks, and reinforce the consistency of interpretation across global programs. Strengthening these foundations ultimately supports more confident decision‑making throughout oncology development.